NASDAQ:KLDO Kaleido Biosciences (KLDO) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume10,597 shsMarket Capitalization$4,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Kaleido Biosciences (NASDAQ:KLDO) StockKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KLDO Stock News HeadlinesJune 3, 2023 | benzinga.comKaleido Creative Studio Launches OnNiche™: A Niche-Based Marketing System for Financial AdvisorsApril 26, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028June 7, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.April 26, 2023 | tmcnet.comKaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028March 28, 2023 | marketwatch.comConsumer & IoT Mobile Roaming Data Traffic Expected to Triple 2019 Volume, Approaching 3,000 Petabytes in 2023: Kaleido IntelligenceFebruary 22, 2023 | yahoo.comDirect-To-Satellite Communications to Generate $9 Billion in Airtime Revenues for Operators in 2030: Kaleido IntelligenceJanuary 27, 2023 | yahoo.comKaleido will compensate all fraudulent withdrawals from its clients' accountsDecember 17, 2022 | seekingalpha.comKLDO Kaleido Biosciences, Inc.June 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.November 10, 2022 | technews.tmcnet.comVoLTE Roaming Readiness Ranked As High Priority For Mobile Operators: Kaleido Q3 2022 Mno SurveySeptember 27, 2022 | tmcnet.comSyniverse Earns Industry Honors in Roaming and Data & Financial Clearing from Kaleido IntelligenceSeptember 12, 2022 | benzinga.comAirlinq, Tata Communications and Giesecke+Devrient, Recognised as Champion Cellular IoT Connectivity Vendors by Kaleido IntelligenceSeptember 5, 2022 | benzinga.comExclusive Free Roaming Insights Available as Kaleido Becomes GSMA MemberAugust 23, 2022 | yahoo.comIPX Networks to Carry 1,900 Petabytes of Consumer & IoT Roaming Data Traffic in 2022: Kaleido IntelligenceJuly 26, 2022 | apnews.comBCE To Provide $5 Billion Operator Revenue Opportunity From Permanently Roaming IoT Devices Over the Next 5 Years: Kaleido IntelligenceJuly 21, 2022 | msn.comEthereum’s Kaleido Collaborates With Polygon for Web3 AdoptionJune 14, 2022 | morningstar.comKaleido Biosciences Inc - Stock Price vs Fair Value KLDOJune 7, 2022 | tmcnet.comSecurity and Design are the biggest knots to untangle, according to the largest-ever IoT connectivity survey run by Kaleido IntelligenceMay 16, 2022 | uk.finance.yahoo.comKaleido Biosciences, Inc. (KLDO)April 15, 2022 | seekingalpha.comATER, HNRG and AGLE among mid-day moversApril 11, 2022 | benzinga.comKaleido Biosciences Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Kaleido Biosciences, Inc.April 8, 2022 | benzinga.comKaleido Biosciences Shares Halted On Code News PendingApril 8, 2022 | finance.yahoo.comKaleido Biosciences Shares Plunging To 52-Week Low, Read WhyApril 8, 2022 | msn.comFlagship’s Kaleido Biosciences shuts down, as more biotechs lay off staffApril 8, 2022 | seekingalpha.comKaleido Biosciences to delist from Nasdaq as business operations endApril 8, 2022 | bizjournals.comKaleido Biosciences shuts downApril 1, 2022 | finance.yahoo.comNovartis (NVS) Beovu Gets Label Expansion for DME in EUSee More Headlines KLDO Company Calendar Last Earnings11/01/2021Today6/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KLDO CUSIPN/A CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$4,000.00 OptionableNot Optionable Beta-0.06 Key ExecutivesMs. Kimberly HocknellSr. VP of Technical OperationsMs. Susan Stewart J.D. (Age 62)L.L.M., Chief Regulatory Affairs Advisor Dr. Mark A. Wingertzahn Ph.D. (Age 51)Sr. VP of R&D and Head of Devel. Key CompetitorsGenocea BiosciencesNASDAQ:GNCAQGenocea BiosciencesNASDAQ:GNCAAllied Healthcare ProductsNASDAQ:AHPIAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All Competitors KLDO Stock - Frequently Asked Questions How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The firm earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK). When did Kaleido Biosciences IPO? (KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Kaleido Biosciences' stock symbol? Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO." How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Kaleido Biosciences make? Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $0.00 and generates $1.10 million in revenue each year. How can I contact Kaleido Biosciences? The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000. This page (NASDAQ:KLDO) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.